[A19-49] Empagliflozin/linagliptin (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V
Last updated 02.09.2019
Commission awarded on 29.05.2019 by the Federal Joint Committee (G-BA).
Digestion, metabolism and hormones
Adults with type 2 diabetes mellitus when diet and exercise plus at least 2 blood-glucose lowering drugs (except insulin, here metformin/sulphonylurea and empagliflozin/linagliptin) do not provide adequate glycaemic control
Added benefit not proven due to a lack of suitable study data
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.